Unresectable HER2-Negative Breast Carcinoma
3 clinical trials · Condition
◉ Watch Unresectable HER2-Negative Breast Carcinoma
| Record | Firm | Date |
|---|---|---|
| Testing the Addition of an Investigational Anti-Cancer Drug, ASTX660 (Tolinapant), to a Usual Chemotherapy Treatment (Eribulin) for Treatment of Advanced Triple Negative Breast Cancer (NCT06590558) | National Cancer Institute (NCI) | 2025-08-04 |
| Olaparib and Alpelisib for Treatment of Metastatic Breast Cancer, A ComboMATCH Treatment Trial (NCT05967286) | National Cancer Institute (NCI) | 2023-10-23 |
| Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial (NCT05564377) | National Cancer Institute (NCI) | 2023-04-07 |
Track Unresectable HER2-Negative Breast Carcinoma automatically
Every clearance here is in the API, with alerts when new ones post.